Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
37.50
-2.69 (-6.69%)
At close: Apr 1, 2025, 4:00 PM
38.50
+1.00 (2.67%)
After-hours: Apr 1, 2025, 5:32 PM EDT
Cytokinetics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 94.86 | 113.02 | 65.58 | 112.67 | 82.99 | Upgrade
|
| Short-Term Investments | 981.16 | 501.8 | 717 | 358.97 | 381.08 | Upgrade
|
| Cash & Short-Term Investments | 1,076 | 614.82 | 782.58 | 471.64 | 464.06 | Upgrade
|
| Cash Growth | 75.01% | -21.44% | 65.93% | 1.63% | 106.15% | Upgrade
|
| Accounts Receivable | 16.65 | 1.28 | 0.15 | 56.82 | 6.92 | Upgrade
|
| Receivables | 16.65 | 1.28 | 0.15 | 56.82 | 6.92 | Upgrade
|
| Prepaid Expenses | 15.28 | 11.94 | 12.46 | 7.22 | 3.24 | Upgrade
|
| Total Current Assets | 1,108 | 628.05 | 795.19 | 535.67 | 474.22 | Upgrade
|
| Property, Plant & Equipment | 140.97 | 147.74 | 163.19 | 146.41 | 16.27 | Upgrade
|
| Long-Term Investments | 145.06 | 40.53 | 46.71 | 152.05 | 36.95 | Upgrade
|
| Other Long-Term Assets | 7.71 | 8 | 9.69 | 7.19 | 6.36 | Upgrade
|
| Total Assets | 1,402 | 824.32 | 1,015 | 841.32 | 533.8 | Upgrade
|
| Accounts Payable | 20.37 | 21.51 | 25.61 | 21.09 | 8.05 | Upgrade
|
| Accrued Expenses | 55.32 | 42.64 | 44.1 | 34.37 | 19.32 | Upgrade
|
| Short-Term Debt | 11.3 | - | - | - | - | Upgrade
|
| Current Portion of Long-Term Debt | 11.52 | 10.08 | 0.96 | - | - | Upgrade
|
| Current Portion of Leases | 19.18 | 17.89 | 12.83 | 14.86 | 2.79 | Upgrade
|
| Current Unearned Revenue | 52.37 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 9.61 | 10.56 | 1.12 | 1.54 | 1.05 | Upgrade
|
| Total Current Liabilities | 179.67 | 102.68 | 84.62 | 71.86 | 31.2 | Upgrade
|
| Long-Term Debt | 768.6 | 607.37 | 609.62 | 142.84 | 135.71 | Upgrade
|
| Long-Term Leases | 112.58 | 120.43 | 126.9 | 112.23 | 0.44 | Upgrade
|
| Long-Term Unearned Revenue | 462.19 | 379.98 | 300.5 | 266.07 | 253.07 | Upgrade
|
| Other Long-Term Liabilities | 14 | 0.19 | 1.04 | 4.46 | - | Upgrade
|
| Total Liabilities | 1,537 | 1,211 | 1,123 | 597.46 | 420.42 | Upgrade
|
| Common Stock | 0.12 | 0.1 | 0.09 | 0.08 | 0.07 | Upgrade
|
| Additional Paid-In Capital | 2,564 | 1,726 | 1,482 | 1,452 | 1,105 | Upgrade
|
| Retained Earnings | -2,702 | -2,112 | -1,586 | -1,208 | -992.31 | Upgrade
|
| Comprehensive Income & Other | 2.4 | -0.01 | -3.59 | -0.87 | 0.15 | Upgrade
|
| Shareholders' Equity | -135.37 | -386.32 | -107.9 | 243.86 | 113.38 | Upgrade
|
| Total Liabilities & Equity | 1,402 | 824.32 | 1,015 | 841.32 | 533.8 | Upgrade
|
| Total Debt | 923.18 | 755.77 | 750.3 | 269.93 | 138.94 | Upgrade
|
| Net Cash (Debt) | 152.83 | -140.95 | 32.28 | 201.71 | 325.12 | Upgrade
|
| Net Cash Growth | - | - | -84.00% | -37.96% | 265.13% | Upgrade
|
| Net Cash Per Share | 1.36 | -1.46 | 0.36 | 2.62 | 5.04 | Upgrade
|
| Filing Date Shares Outstanding | 118.41 | 103 | 95.16 | 84.86 | 71.11 | Upgrade
|
| Total Common Shares Outstanding | 118.21 | 101.64 | 94.83 | 84.8 | 71.02 | Upgrade
|
| Working Capital | 928.27 | 525.37 | 710.57 | 463.81 | 443.02 | Upgrade
|
| Book Value Per Share | -1.15 | -3.80 | -1.14 | 2.88 | 1.60 | Upgrade
|
| Tangible Book Value | -135.37 | -386.32 | -107.9 | 243.86 | 113.38 | Upgrade
|
| Tangible Book Value Per Share | -1.15 | -3.80 | -1.14 | 2.88 | 1.60 | Upgrade
|
| Machinery | 30.82 | 28.16 | 28.45 | 27.48 | 22.99 | Upgrade
|
| Construction In Progress | 4.07 | 0.22 | 0.74 | 0.22 | 9.13 | Upgrade
|
| Leasehold Improvements | 66.87 | 66.87 | 65.91 | 60.34 | 5.87 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.